Expression profiling of O6 methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases

The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy

(2014) Youwei Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma

(2013) Yunli Zhou et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Temozolomide in the management of dopamine agonist-resistant prolactinomas

(2012) B. C. Whitelaw et al.   CLINICAL ENDOCRINOLOGY

Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment

(2012) Gérald Raverot et al.   CLINICAL ENDOCRINOLOGY

Biomarkers of aggressive pituitary adenomas

(2012) Ozgur Mete et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status

(2011) Ann I. McCormack et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline

(2011) Shlomo Melmed et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas

(2011) Fateme Salehi et al.   JOURNAL OF NEURO-ONCOLOGY

MGMT Immunoexpression in Silent Subtype 3 Pituitary Adenomas: Possible Therapeutic Implications

(2010) Michael E. Fealey et al.   ENDOCRINE PATHOLOGY

Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression

(2010) Zachary M. Bush et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience

(2010) Gérald Raverot et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide

(2010) George C. Bobustuc et al.   NEURO-ONCOLOGY

MGMT immunoexpression in aggressive pituitary adenoma and carcinoma

(2010) Queenie Lau et al.   Pituitary

Role of Loss of O6-Methylguanine DNA Methyltransferase (MGMT) Expression in Non-Small Cell Lung Carcinomas (NSCLCs): with Reference to the Relationship with p53 Overexpression

(2010) Na-Hye Myong   Cancer Research and Treatment

O6-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas

(2009) Georg Widhalm et al.   CANCER

Blockade of MGMT Expression by O6 Benzyl Guanine Leads to Inhibition of Pancreatic Cancer Growth and Induction of Apoptosis

(2009) S. D. Konduri et al.   CLINICAL CANCER RESEARCH

High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease

(2009) Akira Takeshita et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours

(2008) Ann I. McCormack et al.   CLINICAL ENDOCRINOLOGY

Promoter methylation of O6-methylguanine-DNA-methyltransferase in lung cancer is regulated by p53

(2008) Ji-Ching Lai et al.   DNA REPAIR